KRAS and neoplasm: Significant intratumoral heterogeneity in FBXW7, PIK3CA, and KRAS expression has been documented between primary tumors and synchronously resected liver metastases in KRAS wild type mCRC during targeted treatment [114], suggesting that FBXW7 may promote both metastatic establishment and tumor heterogeneity, potentially impacting therapeutic response [115].